COMPANY

Procyrion

HQ: Houston, TX source · procyrion.com ↗ · Southwest

Location: Houston, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Heart Failure Cardiorenal Syndrome Cardio-Renal Syndrome Systolic Heart Failure Diastolic Heart Failure Congestive Heart Failure Acute Kidney Injury Heart Failure，Congestive Aortix System

3Trials (company is sponsor)

Raises and deals from press releases

Raise Series E · $57.7M · announced Feb 5, 2024 Company release ↗
Source quote
- Feb 5, 2024 · Company release ↗
  “Procyrion Closes $57.7 Million in Series E Financing”

Raises announced in these releases: $57.7M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Feb 5, 2024 Raise Series E · $57.7M source ↗
Aug 23, 2023 Trial start Not phased (device or behavioral study): Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure source ↗
Jul 17, 2022 Trial start Not phased (device or behavioral study): Aortix Therapy for Perioperative Reduction of Kidney Injury source ↗
Feb 5, 2021 Trial start Not phased (device or behavioral study): The Aortix CRS Pilot Study source ↗

Upcoming milestones

2028-01 (ESTIMATED) · Not phased · Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure · NCT05677100

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05677100	Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure	Not phased (device or behavioral study)	Recruiting	Aug 23, 2023	2028-01 (estimated)
NCT04999163	Aortix Therapy for Perioperative Reduction of Kidney Injury	Not phased (device or behavioral study)	Terminated	Jul 17, 2022	Aug 22, 2023 (actual)
NCT04145635	The Aortix CRS Pilot Study	Not phased (device or behavioral study)	Completed	Feb 5, 2021	Oct 7, 2022 (actual)